IGC Pharma Q1 2025 GAAP EPS $(0.03), Inline, Sales $272.000K Miss $310.000K Estimate
Portfolio Pulse from Benzinga Newsdesk
IGC Pharma reported Q1 2025 GAAP EPS of $(0.03), which met analyst expectations, but sales of $272.000K missed the $310.000K estimate. This represents a 25% improvement in EPS from the previous year but a 50.99% decline in sales.
August 09, 2024 | 5:48 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
IGC Pharma's Q1 2025 earnings per share met expectations, but sales significantly missed estimates, showing a substantial year-over-year decline.
While the EPS met expectations, the significant miss in sales and the large year-over-year decline in revenue are likely to negatively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100